Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Immune Biosolutions
Sort By
Newest First
Sign in
1 / 1
1 / 1
Immunotherapy
Immune Biosolutions Reports That Its Lead Immunotherapy Product IBIO123 Neutralizes 100% of the SARS-CoV-2 Variants of Concern (VOCs), Including Omicron
Immune Biosolutions
PR-M01-22-06
Jan 10, 2022
